Enzyme is Crucial for Combatting Antibiotic-Resistant E. coli Infections

Article

Research by bioscientists at the University of Kent and the University of Queensland is expected to pave the way for new approaches to kill bacteria that no longer respond to conventional antibiotics. In a paper published by Scientific Reports, Kent's Dr. Mark Shepherd and colleagues demonstrate the importance of an enzyme, cytochrome bd-I, for survival of E. coli that is resistant to multiple antibiotics.

Cytochrome bd-I tagged with Green Fluorescent Protein can be visualized in the membrane of E. coli. Courtesy of Dr. Mark Shepherd
 
Research by bioscientists at the University of Kent and the University of Queensland is expected to pave the way for new approaches to kill bacteria that no longer respond to conventional antibiotics. In a paper published by Scientific Reports, Kent's Dr. Mark Shepherd and colleagues demonstrate the importance of an enzyme, cytochrome bd-I, for survival of E. coli that is resistant to multiple antibiotics.

E. coli causes serious conditions including sepsis, bladder infections, kidney failure and dysentery. The human immune system produces nitric oxide to kill invading E. coli, and cytochrome bd-I is shown to provide significant resistance to nitric oxide during infection.

Since cytochrome bd-I is absent in humans, drugs designed to target this enzyme are less likely to be toxic to human cells. In future, targeting cytochrome bd-I with new drugs will render antibiotic-resistant bacteria more susceptible to attack from the host immune system.

Shepherd is a lecturer in microbial biochemistry at Kent's School of Biosciences.

Source: University of Kent

Related Videos
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Related Content